Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas

Hyuni Cho, Seung Yeon Ha, Seol Hee Park, Kiho Park, Yang Seok Chae

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The mutations that occur in the p53 tumor suppressor gene have been studied in various human malignant tumors. However, little is known about this gene in meningiomas. To investigate the relationship and frequency of p53 gene mutations, the p53 polymerase chain reaction-single stranded conformational polymorphism (PCR-SSCP) and immunohistochemical study were performed on the 41 intracranial meningiomas (21 benign, 11 atypical, and 9 malignant). The higher the p53 protein expression rate, the poorer the histologic grade (9.5%, 72.7%, and 88.9% in benign, atypical and malignant meningioma, respectively) (p=0.000). The p53 protein expression rate was higher in recurrent meningioma (71.4%) than in nonrecurrent meningioma (10.5%) (p=0.002). PCR-SSCP method was performed in positive p53 protein immunoreactivity cases. p53 gene mutation rate was higher in the atypical (62.5%) and malignant (25%) meningiomas than in the benign meningioma (0%) (p=0.232). Also, the rate was higher in recurrent menigioma (20%) than in nonrecurrent meningioma (0%) (o=0.495). Among five to eight exons of the p53 gene, the mutation was observed on exon 7 more frequently. In conclusion, p53 immunoreactivity and p53 gene mutation are closely correlated with histologic grade and histologic atypia of intracranial meningiomas. p53 gene mutation would be considered as a useful marker to detect the progression of intracranial meningiomas.

Original languageEnglish
Pages (from-to)199-205
Number of pages7
JournalJournal of Korean Medical Science
Volume14
Issue number2
Publication statusPublished - 1999 Apr 1

Fingerprint

p53 Genes
Meningioma
Mutation
Neoplasms
Single-Stranded Conformational Polymorphism
Exons
Polymerase Chain Reaction
Proteins
Mutation Rate
Tumor Suppressor Genes

Keywords

  • Genes, p53
  • Meningioma, benign, atypical
  • Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. / Cho, Hyuni; Ha, Seung Yeon; Park, Seol Hee; Park, Kiho; Chae, Yang Seok.

In: Journal of Korean Medical Science, Vol. 14, No. 2, 01.04.1999, p. 199-205.

Research output: Contribution to journalArticle

Cho, Hyuni ; Ha, Seung Yeon ; Park, Seol Hee ; Park, Kiho ; Chae, Yang Seok. / Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas. In: Journal of Korean Medical Science. 1999 ; Vol. 14, No. 2. pp. 199-205.
@article{17018f1ae11e41ee84d888f2d20de184,
title = "Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas",
abstract = "The mutations that occur in the p53 tumor suppressor gene have been studied in various human malignant tumors. However, little is known about this gene in meningiomas. To investigate the relationship and frequency of p53 gene mutations, the p53 polymerase chain reaction-single stranded conformational polymorphism (PCR-SSCP) and immunohistochemical study were performed on the 41 intracranial meningiomas (21 benign, 11 atypical, and 9 malignant). The higher the p53 protein expression rate, the poorer the histologic grade (9.5{\%}, 72.7{\%}, and 88.9{\%} in benign, atypical and malignant meningioma, respectively) (p=0.000). The p53 protein expression rate was higher in recurrent meningioma (71.4{\%}) than in nonrecurrent meningioma (10.5{\%}) (p=0.002). PCR-SSCP method was performed in positive p53 protein immunoreactivity cases. p53 gene mutation rate was higher in the atypical (62.5{\%}) and malignant (25{\%}) meningiomas than in the benign meningioma (0{\%}) (p=0.232). Also, the rate was higher in recurrent menigioma (20{\%}) than in nonrecurrent meningioma (0{\%}) (o=0.495). Among five to eight exons of the p53 gene, the mutation was observed on exon 7 more frequently. In conclusion, p53 immunoreactivity and p53 gene mutation are closely correlated with histologic grade and histologic atypia of intracranial meningiomas. p53 gene mutation would be considered as a useful marker to detect the progression of intracranial meningiomas.",
keywords = "Genes, p53, Meningioma, benign, atypical, Recurrence",
author = "Hyuni Cho and Ha, {Seung Yeon} and Park, {Seol Hee} and Kiho Park and Chae, {Yang Seok}",
year = "1999",
month = "4",
day = "1",
language = "English",
volume = "14",
pages = "199--205",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "2",

}

TY - JOUR

T1 - Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas

AU - Cho, Hyuni

AU - Ha, Seung Yeon

AU - Park, Seol Hee

AU - Park, Kiho

AU - Chae, Yang Seok

PY - 1999/4/1

Y1 - 1999/4/1

N2 - The mutations that occur in the p53 tumor suppressor gene have been studied in various human malignant tumors. However, little is known about this gene in meningiomas. To investigate the relationship and frequency of p53 gene mutations, the p53 polymerase chain reaction-single stranded conformational polymorphism (PCR-SSCP) and immunohistochemical study were performed on the 41 intracranial meningiomas (21 benign, 11 atypical, and 9 malignant). The higher the p53 protein expression rate, the poorer the histologic grade (9.5%, 72.7%, and 88.9% in benign, atypical and malignant meningioma, respectively) (p=0.000). The p53 protein expression rate was higher in recurrent meningioma (71.4%) than in nonrecurrent meningioma (10.5%) (p=0.002). PCR-SSCP method was performed in positive p53 protein immunoreactivity cases. p53 gene mutation rate was higher in the atypical (62.5%) and malignant (25%) meningiomas than in the benign meningioma (0%) (p=0.232). Also, the rate was higher in recurrent menigioma (20%) than in nonrecurrent meningioma (0%) (o=0.495). Among five to eight exons of the p53 gene, the mutation was observed on exon 7 more frequently. In conclusion, p53 immunoreactivity and p53 gene mutation are closely correlated with histologic grade and histologic atypia of intracranial meningiomas. p53 gene mutation would be considered as a useful marker to detect the progression of intracranial meningiomas.

AB - The mutations that occur in the p53 tumor suppressor gene have been studied in various human malignant tumors. However, little is known about this gene in meningiomas. To investigate the relationship and frequency of p53 gene mutations, the p53 polymerase chain reaction-single stranded conformational polymorphism (PCR-SSCP) and immunohistochemical study were performed on the 41 intracranial meningiomas (21 benign, 11 atypical, and 9 malignant). The higher the p53 protein expression rate, the poorer the histologic grade (9.5%, 72.7%, and 88.9% in benign, atypical and malignant meningioma, respectively) (p=0.000). The p53 protein expression rate was higher in recurrent meningioma (71.4%) than in nonrecurrent meningioma (10.5%) (p=0.002). PCR-SSCP method was performed in positive p53 protein immunoreactivity cases. p53 gene mutation rate was higher in the atypical (62.5%) and malignant (25%) meningiomas than in the benign meningioma (0%) (p=0.232). Also, the rate was higher in recurrent menigioma (20%) than in nonrecurrent meningioma (0%) (o=0.495). Among five to eight exons of the p53 gene, the mutation was observed on exon 7 more frequently. In conclusion, p53 immunoreactivity and p53 gene mutation are closely correlated with histologic grade and histologic atypia of intracranial meningiomas. p53 gene mutation would be considered as a useful marker to detect the progression of intracranial meningiomas.

KW - Genes, p53

KW - Meningioma, benign, atypical

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0033111001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033111001&partnerID=8YFLogxK

M3 - Article

C2 - 10331568

AN - SCOPUS:0033111001

VL - 14

SP - 199

EP - 205

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 2

ER -